This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia; reperfusion injury	Cyclooxygenase (COX); lactate dehydrogenase (LDH); protein kinase C (PKC)	Studies in rats suggest that the generic COX inhibitor sulindac could help precondition and protect the heart from ischemia- and reperfusion-induced oxidative damage. In a rat model of ischemia and reperfusion injury, sulindac led to smaller infarcts and reduced levels of LDH, a tissue necrosis marker. Next steps include determining whether sulindac can protect skin cells from UV-induced oxidative damage.	Patented by Florida Atlantic University; in-licensed by CHS Resources LLC	Moench, I. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Nov. 2, 2009; doi:10.1073/pnas.0911046106 Contact: Herbert Weissbach, Florida Atlantic University, Boca Raton, Fla. e-mail: hweissba@fau.edu
SciBX 2(44); doi:10.1038/scibx.2009.1630 Published online Nov. 12, 2009				